A Study of the Current and Potential Suppliers of Actinium-225 for Targeted Alpha Therapy
Yazarlar (8)
Wairimu Chege
Waheed Fatima
Umoette James
Alexander Pavlov
Dr. Öğr. Üyesi Mahmut Cüneyt KAHRAMAN Yalova Üniversitesi, Türkiye
Javad Haroon
Oxano Tkhorik
Valery Radchenko
| Makale Türü | Özgün Makale (Diğer hakemli uluslarası dergilerde yayınlanan tam makale) | ||
| Dergi Adı | Networks for Nuclear Innovation | ||
| Dergi ISSN | 2160-8407 Wos Dergi | ||
| Makale Dili | İngilizce | Basım Tarihi | 01-2019 |
| Özet |
| Targeted Alpha Therapy (TAT) is one of the most important treatments for cancer cells. Ac-225 based radiotracers have shown very promising results over the last decades in this treatment. The positive results of Ac-225 radiopharmaceuticals for the treatment of brain tumors, neuroendocrine tumors, melanoma and prostate cancer has led to a demand for more production of Ac-225.Currently, problems in the treatment of cancer using Ac-225 radiopharmaceuticals are the high price and significant gaps between demand and supply. The increasing demand for Ac-225 and the major production routes were discussed to produce a solution to the current problems. These include:" milking" the accumulated Ac-225 from stockpiles of U-233, splitting Th-232 with high-energy proton accelerators, producing Ac-225 from Ra-226 with proton or electron accelerators and the reactor-based method through Ra-226 reaction. The … |
| Anahtar Kelimeler |
